Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ANTEOTECH LTD Capital/Financing Update 2024

Nov 12, 2024

64304_rns_2024-11-12_77976319-b3ba-4789-ab12-8d5c47ce9266.pdf

Capital/Financing Update

Open in viewer

Opens in your device viewer

Non-Renounceable Entitlement Offer

Cleansing Notice under section 708AA(2)(f) of the Corporations Act

BRISBANE, AUSTRALIA, 13 November 2024 : AnteoTech Ltd (ASX:ADO) ( Company ) gives notice under section 708AA(2)(f) of the Corporations Act 2001 (Cth) ( Corporations Act ) as modified by the ASIC Corporations (Non-Traditional Rights Issues) Instrument 2016/84 and ASIC Corporations (Disregarding Technical Relief) Instrument 2016/73 ( ASIC Instruments ). Where applicable, references in this notice to sections of the Corporations Act are to those sections as modified by the ASIC Instruments.

The Company today announced a non-renounceable pro-rata entitlement offer to raise approximately $5 million (before costs) ( Entitlement Offer ).

Under the Entitlement Offer, eligible shareholders will be invited to subscribe for 1 fully paid ordinary share in the Company ( New Share ) for every 10 existing fully paid ordinary shares in the Company held as at 7.00pm (AEST) on 18 November 2024 ( Entitlement ) at an issue price of $0.02 per New Share.

Further details of the Entitlement Offer will be set out in the offer booklet to be released on the Company's ASX market announcements platform on Thursday 21 November 2024 ( Offer Booklet ). In respect of the Entitlement Offer, the Company advises:

  1. The New Shares will be offered without disclosure under Part 6D.2 of the Corporations Act.

  2. This notice is given under section 708AA(2)(f) of the Corporations Act.

  3. As at the date of this notice, the Company has complied with:

    • (a) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and

    • (b) sections 674 and 674A of the Corporations Act.

  4. As at the date of this notice, there is no excluded information of the type referred to in sections 708AA(8) or 708AA(9) of the Corporations Act, that is required to be set out under section 708AA(7) of the Corporations Act; and

  5. The potential effect that the issue of the New Shares will have on the control of the Company, and the consequences of that effect, will depend on a number of factors including the extent that shareholders take up their entitlements and/or any shortfall:

    • (a) if all shareholders take up their entitlements for New Shares, the Entitlement Offer will have no effect on the control of the Company and all shareholders will hold the same percentage interest in the Company; and

    • (b) if there is a shortfall, shareholders who do not subscribe for their full entitlement under the Entitlement Offer will be diluted relative to those shareholders who subscribe for their full entitlement;

however, given the size and pricing of the Entitlement Offer and that currently there are no substantial shareholders, the Entitlement Offer is not expected to have a material effect on consequence on the control of the Company.

This announcement has been authorised for release by the Board of AnteoTech Ltd.

- ENDS -

Media and investor enquiries : +61 7 3219 0085 or [email protected]

Company and Partnering enquiries : David Radford, CEO, on + 61 7 3219 0085

For further information, please check our website www.anteotech.com

About AnteoTech - (ASX:ADO)

AnteoTech is a revenue-stage company that provides solutions for the clean energy and life sciences markets using our proprietary applied materials technology. In the rapidly growing clean energy market, our lead product Anteo X™, has been proven to provide significant improvement in anode performance and the Company has partnered with global suppliers to the lithium-ion battery manufacturing industry. The portfolio includes a proprietary high silicon anode Ultranode™, made with unrefined silicon which offers advantages of size, weight and cost. The Life Sciences division services the Point-of-Care and In vitro diagnostics markets; from global diagnostics companies to technology developers. The unique characteristics of AnteoBind™ provides strong advantages in bioconjugation to rapidly speed up testing procedures and improve accuracy.

AnteoTech - Social Media Policy

AnteoTech is committed to communicating with the investment community through all available channels. Whilst ASX remains the prime channel for market sensitive news, investors and other interested parties are encouraged to follow AnteoTech on LinkedIn. Subscribe to AnteoTech Latest News emails - visit our website at www.anteotech.com and subscribe to receive our email alert service.

Forward Looking Statements

This Announcement may contain forward-looking statements, including estimates, projections and other forward-looking information (Estimates and Projections). Forward-looking statements can generally be identified by the use of forward-looking words such as “expect”, “anticipate”, “likely”, “intend”, “should”, “could”, “may”, “predict”, “plan”, “propose”, “will”, “believe”, “forecast”, “estimate”, “target”, “outlook”, “guidance” and other similar expressions within the meaning of securities laws of applicable jurisdictions and include, but are not limited to, indications of, or guidance or outlook on, future earnings or financial position or performance of AnteoTech. The Estimates and Projections are based on information available to AnteoTech as at the date of the Announcement, are based upon management’s current expectations, estimates, projections, assumptions and beliefs in regards to future events in respect to AnteoTech’ business and the industry in which it operates which may in time prove to be false, inaccurate or incorrect. The Estimates and Projections are provided as a general guide and should not be relied upon as an indication or guarantee of future performance. The bases for these statements are subject to risk and uncertainties that might be out of control of AnteoTech and may cause actual results to differ from the Announcement. No representation, warranty, or guarantee, whether express or implied, is made or given by AnteoTech in relation to any Estimates and Projections, the accuracy, reliability, or reasonableness of the assumptions on which the Estimates and Projections are based, or the process of formulating any Estimates and Projections, including that any Estimates and Projections contained in this Announcement will be achieved. AnteoTech takes no responsibility to make changes to these statements to reflect change of events or circumstances after the release.

==> picture [596 x 206] intentionally omitted <==